- Home
- RMCF vs SNGX Comparison
RMCF vs SNGX Comparison
Compare RMCF & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | SNGX |
|---|---|---|
| Founded | 1981 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 14.4M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | RMCF | SNGX |
|---|---|---|
| Price | $2.40 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 77.9K | ★ 184.2K |
| Earning Date | 01-13-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,638,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $1.12 | $1.09 |
| 52 Week High | $2.60 | $6.23 |
Technical Indicators
Market Signals| Indicator | RMCF | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 68.70 | 37.06 |
| Support Level | $2.21 | $1.27 |
| Resistance Level | $2.60 | $1.41 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.91 | 5.88 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).